Real-world clinical and economic outcomes associated with supplemental oxygen therapy use among patients with fibrosing interstitial lung disease in the United States
Initiation of oxygen therapy in patients with fibrosing ILD is associated with significantly higher mortality, increased hospitalizations, and greater healthcare utilization and costs. However, these findings do not imply that oxygen therapy causes harm; rather, oxygen use likely reflects more advanced or rapidly progressing ILD. These results highlight the need for earlier and more effective interventions to delay disease progression and reduce the burden of care.
Authors
- Sreenivas P. Veeranki (ORCID: https://orcid.org/0000-0002-8645-1990)
- Amy Anderson (ORCID: https://orcid.org/0000-0002-1067-3204)
- Gursimran Basra
- Amy L. Olson (ORCID: https://orcid.org/0000-0002-5368-0412)
- Andrea Steffens
- João A. de Andrade (ORCID: https://orcid.org/0000-0002-3743-4561)
- Joseph Yuan‐Mou Yang (ORCID: https://orcid.org/0000-0003-4081-7157)
- Lee Brekke (ORCID: https://orcid.org/0000-0001-7384-2514)
Institutions
- Optum (United States) (US)
- Boehringer Ingelheim (France) (FR)
- Boehringer Ingelheim (United States) (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- BMC Pulmonary Medicine
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1186/s12890-025-03909-1
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Boehringer Ingelheim